[go: up one dir, main page]

AR074273A1 - Composicion inmunigenica de multiples componentes para la prevencion de la enfermedad estreptococica beta-hemolitica bhs. uso. metodo - Google Patents

Composicion inmunigenica de multiples componentes para la prevencion de la enfermedad estreptococica beta-hemolitica bhs. uso. metodo

Info

Publication number
AR074273A1
AR074273A1 ARP090104260A AR074273A1 AR 074273 A1 AR074273 A1 AR 074273A1 AR P090104260 A ARP090104260 A AR P090104260A AR 074273 A1 AR074273 A1 AR 074273A1
Authority
AR
Argentina
Prior art keywords
seq
acid sequence
polypeptide
identity
nucleic acid
Prior art date
Application number
Other languages
English (en)
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of AR074273A1 publication Critical patent/AR074273A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1275Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Streptococcus (G)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/09Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092Streptococcus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/09Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/16Otologicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10Antimycotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/70Multivalent vaccine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)

Abstract

Reivindicación 1: Una composición inmunogénica que comprende una mezcla de dos o más polipéptidos, cada polipéptido está codificado por una secuencia de ácidos nucleicos que tiene al menos 90% de identidad con una secuencia de ácidos nucleicos seleccionada del grupo que consiste en: (a) C5a peptidasa ("SCP") (Figura 1 (SEQ ID Ns:1)); (b) marco de lectura abierto ("ORF") 554 (Figura 3 (SEQ ID Ns:3)); (c) ORF 1218 (Figura 5 (SEQ ID Ns:5)); (d) ORF 1358 (Figura 7 (SEQ ID Ns:7)); y (e) ORF 2459 (Figura 9 (SEQ ID Ns:9)). Reivindicación 3: La composición inmunogénica de acuerdo con la reivindicación 1, que además comprende una cantidad efectiva de adyuvante. Reivindicación 4: La composición inmunogénica de acuerdo con la reivindicación 1 en donde cada polipéptido es capaz de generar un anticuerpo que reconoce en forma específica dicho polipéptido, y en donde la cantidad de dicha composición inmunogénica es efectiva para prevenir o mejorar la colonización o infección con estreptococos beta-hemolíticos en un mamífero susceptible. Reivindicación 9: Una composición inmunogénica que comprende una mezcla de dos o más polipéptidos, cada polipéptido que tiene al menos 90% de identidad con una secuencia de aminoácidos seleccionada del grupo que consiste en: (a) SCP (Figura 2 (SEQ ID Ns:2)); (b) peptidilpropil isomerasa (Figura 4 (SEQ ID Ns:4)); (c) proteína hipotética (Figura 6 (SEQ ID Ns:6)); (d) proteína de adhesión putativa (Figura 8 (SEQ ID Ns:8)); y (e) lipoproteína de superficie (Figura 10 (SEQ ID Ns:10)). Reivindicación 27: Una composición inmunogénica que comprende una mezcla de: (a) un polipéptido de SCP codificado por una secuencia de ácidos nucleicos que tiene al menos 90% de identidad con la secuencia de ácidos nucleicos de la Figura 1 (SEQ ID Ns:1); (b) un polipéptido de peptidilpropil isomerasa codificado por una secuencia de ácidos nucleicos que tiene al menos 90% de identidad con la secuencia de ácidos nucleicos de la Figura 3 (SEQ ID Ns:3); y (c) al menos otro polipéptido codificado por una secuencia de ácidos nucleicos que tiene al menos 90% de identidad con una secuencia de ácidos nucleicos seleccionada del grupo que consiste en (i) Figura 5 (SEQ ID Ns:5); (ii) Figura 7 (SEQ ID Ns:7); y (iii) Figura 9 (SEQ ID Ns:9). Reivindicación 35: Una composición inmunogénica que comprende una mezcla de: (a) un polipéptido de SCP que tiene al menos 90% de identidad con la secuencia de aminoácidos de la Figura 2 (SEQ ID Ns:2); (b) un polipéptido de peptidilpropil isomerasa que tiene al menos 90% de identidad con la secuencia de aminoácidos de Figura 4 (SEQ ID Ns:4); y (c) al menos otro polipéptido que tiene al menos 90% de identidad con una secuencia de aminoácidos seleccionada del grupo que consiste en (i) Figura 6 (SEQ ID Ns:6); (ii) Figura 8 (SEQ ID Ns:8); y (iii) Figura 10 (SEQ ID Ns:10).
ARP090104260 2008-11-05 2009-11-04 Composicion inmunigenica de multiples componentes para la prevencion de la enfermedad estreptococica beta-hemolitica bhs. uso. metodo AR074273A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11148508P 2008-11-05 2008-11-05

Publications (1)

Publication Number Publication Date
AR074273A1 true AR074273A1 (es) 2011-01-05

Family

ID=41571714

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP090104260 AR074273A1 (es) 2008-11-05 2009-11-04 Composicion inmunigenica de multiples componentes para la prevencion de la enfermedad estreptococica beta-hemolitica bhs. uso. metodo

Country Status (21)

Country Link
US (2) US8563001B2 (es)
EP (1) EP2356135B1 (es)
JP (1) JP2012508174A (es)
KR (1) KR20110081282A (es)
CN (2) CN107050442B (es)
AR (1) AR074273A1 (es)
AU (1) AU2009313615B2 (es)
BR (1) BRPI0921286B8 (es)
CA (1) CA2741691C (es)
CO (1) CO6382162A2 (es)
DK (1) DK2356135T3 (es)
ES (1) ES2648231T3 (es)
IL (1) IL212491A0 (es)
MX (1) MX2011004755A (es)
NO (1) NO2356135T3 (es)
NZ (2) NZ592368A (es)
PE (1) PE20120116A1 (es)
RU (1) RU2478396C2 (es)
TW (1) TW201022442A (es)
WO (1) WO2010053986A1 (es)
ZA (1) ZA201102894B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2356135B1 (en) * 2008-11-05 2017-10-25 Wyeth LLC Multicomponent immunogenic composition for the prevention of beta-hemolytic streptococcal (bhs) disease
EP3034516A1 (en) 2014-12-19 2016-06-22 Novartis AG Purification of streptococcal capsular polysaccharide
US10738338B2 (en) 2016-10-18 2020-08-11 The Research Foundation for the State University Method and composition for biocatalytic protein-oligonucleotide conjugation and protein-oligonucleotide conjugate
TWI598360B (zh) * 2016-12-19 2017-09-11 義守大學 Fsbm重組蛋白及其用途
RU2708558C1 (ru) * 2018-12-13 2019-12-09 Российская Федерация, от имени которой выступает ФОНД ПЕРСПЕКТИВНЫХ ИССЛЕДОВАНИЙ Способ создания противоопухолевой иммунологической защиты к клеткам лимфомы EL-4

Family Cites Families (112)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4152411A (en) 1977-07-27 1979-05-01 Akzona Incorporated High specific activity labeled substances
US4346074A (en) 1978-08-24 1982-08-24 National Research Development Corp. Pasteurellosis vaccines
US5077044A (en) 1980-05-19 1991-12-31 The Board Of Trustees Of The Leland Stanford Jr. University Novel non-reverting shigella live vaccines
US4837151A (en) 1980-05-19 1989-06-06 The Board Of Trustees Of The Leland Stanford Junior University, Stanford University Live vaccines comprising two mutations and foreign antigen
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US5097020A (en) 1983-07-05 1992-03-17 The University Of Rochester Immunogenic conjugates
US5360897A (en) 1981-08-31 1994-11-01 The University Of Rochester Immunogenic conjugates of streptococcus pneumonial capsular polymer and toxin or in toxiad
US4902506A (en) 1983-07-05 1990-02-20 The University Of Rochester Immunogenic conjugates
US4673574A (en) 1981-08-31 1987-06-16 Anderson Porter W Immunogenic conjugates
US4454121A (en) 1982-07-27 1984-06-12 The University Of Tennessee Research Corporation Synthetic peptides corresponding to antigenic determinants of the M protein of Streptococcus pyogenes
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4650764A (en) 1983-04-12 1987-03-17 Wisconsin Alumni Research Foundation Helper cell
US4784948A (en) 1983-08-10 1988-11-15 The Rockefeller University Production of streptococcal m protein immunogens and molecular probes
US4695562A (en) 1984-04-06 1987-09-22 Univ. Of Tennessee Research Corp. Synthetic peptide compounds
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
GB8424757D0 (en) 1984-10-01 1984-11-07 Pasteur Institut Retroviral vector
US4720489A (en) 1984-10-15 1988-01-19 Douglas Shander Hair growth modification with ornithine decarboxylase inhibitors
FR2573436B1 (fr) 1984-11-20 1989-02-17 Pasteur Institut Adn recombinant comportant une sequence nucleotidique codant pour un polypeptide determine sous le controle d'un promoteur d'adenovirus, vecteurs contenant cet adn recombinant, cellules eucaryotes transformees par cet adn recombinant, produits d'excretion de ces cellules transformees et leurs applications, notamment a la constitution de vaccins
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4797368A (en) 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
US4666829A (en) 1985-05-15 1987-05-19 University Of California Polypeptide marker for Alzheimer's disease and its use for diagnosis
US5078996A (en) 1985-08-16 1992-01-07 Immunex Corporation Activation of macrophage tumoricidal activity by granulocyte-macrophage colony stimulating factor
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
US4772584A (en) 1986-05-23 1988-09-20 Cleary Paul P Inhibitor of C5a-mediated chemotaxis
IT1216262B (it) 1986-09-02 1990-02-22 Bargellini Andrea Assorbente,ed utensile cosi'procedimento ed attrezzatura per la realizzato. formazione di un utensile di pulizia a strisce di materiale
EP0272929B1 (en) 1986-12-24 1996-03-20 Genentech, Inc. Enkephalinase for therapeutic use
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US5124153A (en) 1987-08-24 1992-06-23 University Of Tennessee Research Corp. Therapeutic compositions against streptococcal infections, transformed hosts, methods of immunization and genetically engineered products
US5162226A (en) 1987-08-24 1992-11-10 University Of Tennessee Research Corp. (U.T.R.C.) Therapeutic compositions against streptococcal infections, transformed hosts, methods of immunization and genetically engineered products
CA1315719C (en) 1988-02-05 1993-04-06 Arthur Bank Retroviral packaging cell lines and processes of using same
DE68926427T2 (de) 1988-03-25 1996-12-05 Univ Rockefeller Vom streptococcus m-protein abgeleitete synthetische peptide und damit hergestellte impfstoffe
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
JP3082204B2 (ja) 1988-09-01 2000-08-28 ホワイトヘッド・インスティチュート・フォー・バイオメディカル・リサーチ 両栄養性および環境栄養性宿主域を持つ組換え体レトロウイルス
JP2871709B2 (ja) 1988-11-21 1999-03-17 住友製薬株式会社 免疫グロブリンg結合活性を有する新規な蛋白質プロテインh、該蛋白質をコードする遺伝子及び該蛋白質の製造法
US5354844A (en) 1989-03-16 1994-10-11 Boehringer Ingelheim International Gmbh Protein-polycation conjugates
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
CA2039921A1 (en) 1990-04-16 1991-10-17 Xandra O. Breakefield Transfer and expression of gene sequences into central nervous system cells using herpes simplex virus mutants with deletions in genes for viral replication
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
WO1991018088A1 (en) 1990-05-23 1991-11-28 The United States Of America, Represented By The Secretary, United States Department Of Commerce Adeno-associated virus (aav)-based eucaryotic vectors
SE9002212D0 (sv) 1990-06-21 1990-06-21 Hightech Receptor Ab Igg binding protein
ATE127839T1 (de) 1990-07-31 1995-09-15 Genentech Inc Varianten des gewebeplasminogenaktivators mit vermindertem abbau.
WO1992005263A1 (en) 1990-09-25 1992-04-02 Cantab Pharmaceuticals Research Limited Viral defective vaccine produced by transcomplementing cell line
US5173414A (en) 1990-10-30 1992-12-22 Applied Immune Sciences, Inc. Production of recombinant adeno-associated virus vectors
IL101715A (en) 1991-05-02 2005-06-19 Amgen Inc Recombinant dna-derived cholera toxin subunit analogs
US6100380A (en) 1991-10-28 2000-08-08 Cytran, Inc. Immunomodulating peptides and methods of use
US5252479A (en) 1991-11-08 1993-10-12 Research Corporation Technologies, Inc. Safe vector for gene therapy
AU668908B2 (en) 1992-01-08 1996-05-23 Rockefeller University, The Multifunctional surface protein of streptococci
CA2131703C (en) 1992-03-09 2007-08-21 James C. Paulson Compositions and methods for the identification and synthesis of sialyltransferases
WO1993021220A1 (en) 1992-04-08 1993-10-28 The Council Of The Queensland Institute Of Medical Research Synthetic peptides useful in a vaccine against and in the diagnosis of streptococcal infection
ES2170075T3 (es) 1992-09-16 2002-08-01 Univ Tennessee Res Corp Vacuna de proteina m recombinante multivalente.
DK0618813T3 (da) 1992-09-16 2002-03-11 Univ Tennessee Res Corp Antigen for M-hybridprotein og bærer for gruppe A streptococcal vaccine
EP1024198A3 (en) 1992-12-03 2002-05-29 Genzyme Corporation Pseudo-adenoviral vectors for the gene therapy of haemophiliae
US5593972A (en) 1993-01-26 1997-01-14 The Wistar Institute Genetic immunization
AU696336B2 (en) 1993-03-19 1998-09-10 Cantab Pharmaceuticals Research Limited Defective mutant non-retroviral virus (e.g. HSV) as vaccine
FR2705361B1 (fr) 1993-05-18 1995-08-04 Centre Nat Rech Scient Vecteurs viraux et utilisation en thérapie génique.
FR2705686B1 (fr) 1993-05-28 1995-08-18 Transgene Sa Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
NZ269156A (en) 1993-07-13 1996-03-26 Rhone Poulenc Rorer Sa Defective recombinant adenovirus vector incapable of replicating autonomously in a target cell and its use in gene therapy
US5906928A (en) 1993-07-30 1999-05-25 University Of Medicine And Dentistry Of New Jersey Efficient gene transfer into primary murine lymphocytes obviating the need for drug selection
FR2714830B1 (fr) 1994-01-10 1996-03-22 Rhone Poulenc Rorer Sa Composition contenant des acides nucléiques, préparation et utilisations.
FR2715847B1 (fr) 1994-02-08 1996-04-12 Rhone Poulenc Rorer Sa Composition contenant des acides nucléiques, préparation et utilisations.
FR2716459B1 (fr) 1994-02-22 1996-05-10 Univ Paris Curie Système hôte-vecteur utilisable en thérapie génique.
AU2194895A (en) 1994-03-25 1995-10-17 Uab Research Foundation, The Composition and methods for creating syngeneic recombinant virus-producing cells
EP0753069A1 (en) 1994-04-15 1997-01-15 Targeted Genetics Corporation Gene delivery fusion proteins
US5571515A (en) 1994-04-18 1996-11-05 The Wistar Institute Of Anatomy & Biology Compositions and methods for use of IL-12 as an adjuvant
US5866135A (en) * 1994-04-21 1999-02-02 North American Vaccine, Inc. Group A streptococcal polysaccharide immunogenic compositions and methods
US5505947A (en) 1994-05-27 1996-04-09 The University Of North Carolina At Chapel Hill Attenuating mutations in Venezuelan Equine Encephalitis virus
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US5679654A (en) 1994-09-02 1997-10-21 Brigham & Women's Hospital, Inc. Capsular polysaccharide immunomodulator
US5837533A (en) 1994-09-28 1998-11-17 American Home Products Corporation Complexes comprising a nucleic acid bound to a cationic polyamine having an endosome disruption agent
FR2727679B1 (fr) 1994-12-05 1997-01-03 Rhone Poulenc Rorer Sa Nouveaux agents de transfection et leurs applications pharmaceutiques
IL116816A (en) 1995-01-20 2003-05-29 Rhone Poulenc Rorer Sa Cell for the production of a defective recombinant adenovirus or an adeno-associated virus and the various uses thereof
FR2730637B1 (fr) 1995-02-17 1997-03-28 Rhone Poulenc Rorer Sa Composition pharmaceutique contenant des acides nucleiques, et ses utilisations
US7153510B1 (en) 1995-05-04 2006-12-26 Yale University Recombinant vesiculoviruses and their uses
AU6043396A (en) 1995-06-05 1996-12-24 University Of Alabama At Birmingham Research Foundation, The Composition and methods for creating syngeneic recombinant v irus-producing cells
FR2741358B1 (fr) 1995-11-17 1998-01-02 Centre Nat Rech Scient Production de vecteurs retroviraux par l'intermediaire de vecteurs viraux a base de virus a adn
US6355255B1 (en) 1998-12-07 2002-03-12 Regents Of The University Of Minnesota Streptococcal C5a peptidase vaccine
US5846547A (en) 1996-01-22 1998-12-08 Regents Of The University Of Minnesota Streptococcal C5a peptidase vaccine
US5829302A (en) 1996-05-31 1998-11-03 The National Machinery Company Cassette tooling
IT1289387B1 (it) 1996-07-16 1998-10-02 Zanussi Elettromecc Perfezionamenti ai circuiti refrigeranti a compressione per apparecchi domestici e simili
KR20000048628A (ko) 1996-09-27 2000-07-25 윌리암 에이취 캘넌, 에곤 이 버그 모노네가비랄레스 목의 바이러스에서 감쇠를 책임지는 3' 게놈프로모터 영역 및 폴리머라제 유전자 돌연변이
US6113918A (en) 1997-05-08 2000-09-05 Ribi Immunochem Research, Inc. Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
DE69826124T3 (de) 1997-06-30 2007-10-11 Institut Gustave Roussy Verabreichung der nukleinsäure in den quergestreiften muskel
KR20010014298A (ko) 1997-06-30 2001-02-26 아방티 파르마 소시에테 아노님 핵산 벡터의 생체 내 조직으로의 적정화된 전기전달 장치
CA2294802A1 (fr) 1997-06-30 1999-01-14 Michel Bureau Amelioration du transfert d'acide nucleique dans les cellules d'organismes eucaryotes pluricellulaires et combinaison permettant la mise en oeuvre du procede
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
JP4673974B2 (ja) 1998-09-30 2011-04-20 ワイス・ホールディングズ・コーポレイション アジュバントとしての変異コレラホロトキシン
US6168911B1 (en) 1998-12-18 2001-01-02 Eastman Kodak Company Formulations for preparing metal oxide-based pigment-binder transparent electrically conductive layers
AU762100B2 (en) 1998-12-22 2003-06-19 University Of Tennessee Research Corporation, The Protective antigen of group A Streptococci (SPA)
EP1075841A1 (en) 1999-08-13 2001-02-14 Erasmus Universiteit Rotterdam Pneumococcal vaccines
US7256265B2 (en) 1999-12-03 2007-08-14 Regents Of The University Of Minnesota Streptococcal C5a peptidase vaccine
ATE439372T1 (de) * 2000-10-27 2009-08-15 Novartis Vaccines & Diagnostic Nukleinsäuren und proteine von gruppen a und b- streptokokken
WO2002077183A2 (en) 2001-03-21 2002-10-03 Elitra Pharmaceuticals, Inc. Identification of essential genes in microorganisms
KR100923598B1 (ko) * 2001-04-13 2009-10-23 와이어쓰 스트렙토코커스 피오게네스의 표면 단백질
EP2287311A1 (en) * 2003-03-04 2011-02-23 Intercell AG Streptococcus pyogenes antigens
CN100579985C (zh) * 2003-05-07 2010-01-13 英特塞尔股份公司 无乳链球菌抗原ⅰ和ⅱ
PT1648500E (pt) * 2003-07-31 2014-10-10 Novartis Vaccines & Diagnostic Composições imunogénicas para estreptococos piogenes
RU2263143C2 (ru) * 2004-01-05 2005-10-27 ГНУ Научно-исследовательский институт пушного звероводства и кролиководства им. В.А. Афанасьева Штамм бактерий streptococcus pyogenes №289, используемый для изготовления вакцин против стрептококкоза пушных зверей
WO2005076010A2 (en) 2004-02-06 2005-08-18 Council Of Scientific And Industrial Research Computational method for identifying adhesin and adhesin-like proteins of therapeutic potential
RU2007103831A (ru) * 2004-07-01 2008-08-10 Дайити Фармасьютикал Ко., Лтд. (JP) Производные пиразола
EP1927597B1 (en) * 2004-08-18 2016-11-02 Novabiotics Limited Antibacterial peptides
AU2005294275B2 (en) * 2004-10-08 2012-09-13 Glaxosmithkline Biologicals S.A. Immunogenic and therapeutic compositions for Streptococcus pyogenes
AU2005323534A1 (en) 2005-01-05 2006-07-13 Philip S. Portoghese Analgesic conjugates
US7531541B2 (en) 2005-09-20 2009-05-12 Vanderbilt University Partial mGluR5 antagonists for treatment of anxiety and CNS disorders
AU2009259951A1 (en) * 2008-06-20 2009-12-23 Wyeth Llc Compositions and methods of use of ORF 554 from beta hemolytic Streptococcal strains
WO2009155484A2 (en) * 2008-06-20 2009-12-23 Wyeth Compositions and methods of use of orf1358 from beta-hemolytic streptococcal strains
EP2356135B1 (en) * 2008-11-05 2017-10-25 Wyeth LLC Multicomponent immunogenic composition for the prevention of beta-hemolytic streptococcal (bhs) disease

Also Published As

Publication number Publication date
TW201022442A (en) 2010-06-16
BRPI0921286A2 (pt) 2015-03-24
CN107050442A (zh) 2017-08-18
RU2011116286A (ru) 2012-12-20
ES2648231T3 (es) 2017-12-29
CA2741691A1 (en) 2010-05-14
DK2356135T3 (en) 2017-12-04
RU2478396C2 (ru) 2013-04-10
NZ614064A (en) 2015-04-24
US20140037669A1 (en) 2014-02-06
MX2011004755A (es) 2011-10-10
CO6382162A2 (es) 2012-02-15
US9127050B2 (en) 2015-09-08
BRPI0921286B8 (pt) 2022-10-25
NZ592368A (en) 2013-11-29
IL212491A0 (en) 2011-06-30
PE20120116A1 (es) 2012-02-18
WO2010053986A1 (en) 2010-05-14
CA2741691C (en) 2019-11-26
KR20110081282A (ko) 2011-07-13
US20100119534A1 (en) 2010-05-13
EP2356135A1 (en) 2011-08-17
EP2356135B1 (en) 2017-10-25
BRPI0921286A8 (pt) 2018-01-02
NO2356135T3 (es) 2018-03-24
AU2009313615A1 (en) 2010-05-14
JP2012508174A (ja) 2012-04-05
ZA201102894B (en) 2012-06-27
CN107050442B (zh) 2022-09-13
AU2009313615B2 (en) 2012-11-29
US8563001B2 (en) 2013-10-22
BRPI0921286B1 (pt) 2021-11-23
CN102203122A (zh) 2011-09-28

Similar Documents

Publication Publication Date Title
RU2508126C2 (ru) Композиции для иммунизации против staphylococcus aureus
PE20121685A1 (es) Antigeno ndv recombinante y usos del mismo
ES2540858T3 (es) Composición farmacéutica para el tratamiento y/o la prevención de cáncer
AR064642A1 (es) Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
AR107020A2 (es) Vacuna de pcsk9 (proteína convertasa subtilisina-kexina tipo 9)
ES2545895T3 (es) Proteína de fusión anticancerígena
CO5700788A2 (es) Composiciones y metodos para inmunoterapia especifica de wt1
EA201270517A1 (ru) Микобактериальные вакцины
JP2012523246A5 (es)
CO6150189A2 (es) Vacunas para malaria
UA110806C2 (uk) Мікобактеріальна антигенна композиція
AR036160A1 (es) Regulacion de las vias metabolicas lipidicas en las plantas, mediante transgenesis con sentido o antisentido de factores de transcripcion hap2, hap5 y hap3/lec1
MX337417B (es) Vacunas peptidicas para canceres que expresan antigenos asociados con tumores.
AR093186A1 (es) Proteinas de union al antigeno cd27l
JP2012501959A5 (es)
IN2014KN01713A (es)
EA200801221A1 (ru) Вирусные вакцины, полученные из клеток, с низкими уровнями остаточной клеточной днк
MX358725B (es) Antigenos prostaticos de consenso, molecula de acido nucleico que los codifica y vacuna y usos que los comprenden.
EE200100203A (et) Meetod immuunvastuse indutseerimiseks polüpeptiidse antigeeni vastu ja rakuga seotud polüpeptiidse antigeeni mahasurumiseks loomorganismil, selle meetodi kasutamine eesnäärme- ja rinnavähi raviks ning immunogeenne kompositsioon
AR085281A1 (es) Moduladores de la proteina tirosina quinasa 7 (ptk7) y metodos para su uso
CO6700829A2 (es) Moduladores novedosos y métodos de uso
AR085167A1 (es) Polipeptidos de porphyromonas gingivalis, metodo de tratamiento, uso, anticuerpo y kit
EA200700849A1 (ru) Первичная/бустерная противомалярийная вакцина
AR074273A1 (es) Composicion inmunigenica de multiples componentes para la prevencion de la enfermedad estreptococica beta-hemolitica bhs. uso. metodo
CO6491059A2 (es) Diferenciacion de las celulas madre mesenquimales

Legal Events

Date Code Title Description
FA Abandonment or withdrawal